Navigation Links
PreMD Inc. Completes Debenture Financing
Date:3/12/2008

TORONTO, March 12 /PRNewswire-FirstCall/ - Predictive medicine company PreMD Inc. (TSX: PMD; Amex: PME) ("PreMD" or the "Company") today announced that it has completed its previously announced debenture financing with several existing institutional investors and insiders, including Midsummer Investment, Ltd. The gross proceeds of the financing totaled approximately CDN$1.22 million, and will be used for general corporate expenses, with a focus on the Company's appeal to the US Food and Drug Administration (FDA) regarding its recent 510(k) submission.

"We are very pleased to have this financial backing at this time," said Dr. Brent Norton, president and CEO of PreMD. "We are facing some challenges, but with our FDA appeal underway and existing clinical trials continuing, this financing gives us the time we need to see the business through 2008. We hope to quickly resolve our FDA issues and proceed with the commercialization of our skin cholesterol test in the US market."

The unsecured debentures mature 18 months after the date of issuance at an amount equal to CDN$1,176 per CDN$1,000 principal amount. The Company has agreed to certain pre-payable forced redemptions at the option of the holders or the Company. The Company has also issued approximately five million common share purchase warrants (the "Warrants"), each Warrant being exercisable for a period of five years into one common share at $0.2759, a price equal to 100% of the 5-day volume-weighted average price of the common shares on the Toronto Stock Exchange.

About PreMD Inc.

PreMD Inc. is a leader in predictive medicine, dedicated to developing rapid, non-invasive tests for the early detection of life-threatening diseases. PreMD's cardiovascular products include a line of non-invasive skin cholesterol tests. PreMD's other skin cholesterol products include PREVU(x) LT, a skin cholesterol test designed for use in the life insurance industry. The Company's cancer tests include
'/>"/>

SOURCE PreMD Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. PreMD Inc. Signs Agreement with Cosmetics Conglomerate
2. PreMD Inc. Announces Debenture Financing
3. PreMD Initiates FDA Review Process and Provides Corporate Update
4. PreMD Announces FDA Decision on POC Skin Cholesterol Test
5. PreMD Announces Valuable Data on PREVU(x) LT Life Insurance Product
6. PreMD Inc. Provides Corporate Update
7. PreMD Provides Update on 510(k) Application for PREVU(x) POC
8. Gentiva(R) Health Services Completes Acquisition of Major Home Health Provider in CON State of Mississippi
9. Roche Completes Tender Offer for Ventana Shares
10. Nyer Medical Group Completes Acquisition of Minority Interest in Pharmacy Chain Subsidiary; Former Minority Shareholders Invest in Nyer Medical Group and Sign 3-Year Employment Agreements
11. KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 In its latest blog post, ... believes that having family close by during a stay in ... the process is successful, is highlighting a member of the ... the lives of addicts across the country and around the ... can reduce the blood pressure, heart rate, and stress levels ...
(Date:9/17/2014)... sound like the ideas of a science fiction ... an exciting new approach to imaging local and ... prostate cancer, scientists at Virginia Commonwealth University Massey ... Johns Hopkins Medical Institutions have provided proof-of-principle of ... doctors, ability to see tumors that have metastasized ...
(Date:9/17/2014)... NY (PRWEB) September 17, 2014 In ... acknowledges that “bi-weekly telephonic discovery conferences would be beneficial ... such conferences through mid-December. “At the end of December,” ... assess the need for additional conferences. , “The ... recognizes that there is still much to be discussed ...
(Date:9/17/2014)... Dennis Thompson HealthDay Reporter ... in the womb to household chemicals known as phthalates ... Columbia University researchers reported in a new study. ... developing asthma between age 5 and 11 if their ... two phthalates (pronounced thal-ates), the researchers found. The two ...
(Date:9/17/2014)... The Scripps Research Institute (TSRI) have devised a ... effective against vancomycin-resistant strains of MRSA and other ... to have not one but two distinct mechanisms ... evolve resistance quickly. , "This is the prototype ... in clinical use a generation or maybe even ...
Breaking Medicine News(10 mins):Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 3
... tend to outlive males, a circumstance that is usually ... especially when they compete for females. This might also ... higher parasite burden than females. Therefore, high variability of ... be more important for males. Scientists at the Research ...
... tests should not be used to predict Alzheimer,s disease, the ... Although there is a link between the two, ... their sense of smell, and it may not necessarily mean ... "A nonspecific association between poor smell function and Alzheimer,s ...
... THURSDAY, May 10 (HealthDay News) -- A new weight-loss ... and Drug Administration showed promising results in a recent ... a combination of the drugs phentermine and topiramate, experienced ... health problems, the study found. The findings were reported ...
... privately insured colon cancer patients found that managed care presence ... surgery to treat colon cancer lowered costs, a national team ... University School of Public Health and Health Services reported in ... cancer is the second leading cause of cancer death in ...
... from systemic sclerosis, also known as scleroderma, than Caucasians. ... a journal of the American College of Rheumatology (ACR), ... likely to have antibodies that increased frequency and severity ... According to the ACR there are 49,000 ...
... Chronic exposure to cocaine reduces the expression of a ... in vivo research on the molecular basis of cocaine ... which produce greater sensitivity to the rewarding effects of ... for development of a treatment for cocaine addiction. It ...
Cached Medicine News:Health News:Living longer - variability in infection-fighting genes can be a boon for male survival 2Health News:Smell Tests Don't Predict Alzheimer's, Study Finds 2Health News:New Weight-Loss Drug Shows Promise in Trial 2Health News:New Weight-Loss Drug Shows Promise in Trial 3Health News:Economic theory actually works in health care 2Health News:Systemic sclerosis complications more severe in African Americans than Caucasians 2Health News:Chronic cocaine use triggers changes in brain's neuron structure 2
(Date:9/17/2014)... YORK , Sept. 17, 2014  Levi & ... in connection with possible claims of breaches of fiduciary ... To get more information, click here: ... you. If you own common stock in ... please contact Eduard Korsinsky, Esq. either via ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire-iReach/ -- ... white paper discussing improvements in the development ... structures for both normal and diseased tissue ... information, simplifies surgical procedures, lowers surgical costs ... surgical procedures. The clinical ...
(Date:9/17/2014)... , Sept. 17, 2014 Bronstein, Gewirtz & ... purchasers of the securities of PDL BioPharma, Inc. ("PDL ... -News).  Such investors are advised to contact Peretz ... Kimelman at info@bgandg.com or 212-697-6484. ... certain of its executives violated federal securities laws. ...
Breaking Medicine Technology:Patient Outcomes Improve When Molecular Chemical Imaging Technology Is Used to Aid Robotic Surgical Procedures, According to New White Paper 2Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
... The Repeater Plus, a handheld manual ... saving time on long series pipetting. Its ... exceptional support for research tasks, and its ... with repetitive work. The nine Combitips allow ...
eValuator fixed-curve diagnostic electrophysiology catheters offer an effective balance between clinical performance and cost....
The True Non-Compliant Balloon....
Medicine Products: